Computational strategies for PROTAC drug discovery

Computational strategies for PROTAC drug discovery

Proteolysis-targeting chimeras (PROTACs), a novel targeted protein degradation technology for potential clinical drug discovery, is composed of a protein-targeting ligand covalently linked to an E3 ligase ligand. Through recruiting E3 ligase to target proteins, PROTACs elicit ubiquitination and subs...

Full description

Bibliographic Details
Main Authors:	Jia Wu, Wanhe Wang, Chung-Hang Leung
Format:	Article
Language:	English
Published:	Compuscript Ltd 2023-02-01
Series:	Acta Materia Medica
Subjects:	protac virtual screening molecular docking e3 ligase degradation protein-protein interaction small-molecule drug discovery
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2022-0041

Similar Items

Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
by: Hany S. Ibrahim, et al.
Published: (2021-07-01)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01)

PROTACs: A novel strategy for cancer drug discovery and development
by: Xin Han, et al.
Published: (2023-06-01)

PROTACs in gastrointestinal cancers
by: Yu Chen, et al.
Published: (2022-12-01)

Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
by: Marcin Cieślak, et al.
Published: (2023-03-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-12-01)

Recent Advances in PROTACs for Drug Targeted Protein Research
by: Tingting Yao, et al.
Published: (2022-09-01)

Photocontrollable PROTAC molecules: Structure and mechanism of action
by: Koravović Mladen, et al.
Published: (2021-01-01)

An overview of PROTACs: a promising drug discovery paradigm
by: Zi Liu, et al.
Published: (2022-12-01)

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation
by: Ming He, et al.
Published: (2021-06-01)

Mapping the energy landscape of PROTAC-mediated protein-protein interactions
by: José A. Villegas, et al.
Published: (2023-01-01)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
by: Minoru Ishikawa, et al.
Published: (2020-04-01)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
by: Yonghan He, et al.
Published: (2020-07-01)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
by: Si-Min Qi, et al.
Published: (2021-05-01)

Discovery of E3 Ligase Ligands for Target Protein Degradation
by: Jaeseok Lee, et al.
Published: (2022-10-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022-08-01)

Current strategies for the design of PROTAC linkers: a critical review
by: Robert I. Troup, et al.
Published: (2020-10-01)

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
by: Xin Han, et al.
Published: (2022-05-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
by: Xuelian Liu, et al.
Published: (2023-01-01)

Targeting Protein Kinases Degradation by PROTACs
by: Fei Yu, et al.
Published: (2021-06-01)

News from DMCCB – Targeted Protein Degradation
by: Georg Jaeschke
Published: (2018-12-01)

Recent Advances in PROTAC-Based Antiviral Strategies
by: Haleema Ahmad, et al.
Published: (2023-01-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)

PROTACs for BRDs proteins in cancer therapy: a review
by: Chao Wang, et al.
Published: (2022-12-01)

Key Considerations in Targeted Protein Degradation Drug Discovery and Development
by: Liena Qin, et al.
Published: (2022-08-01)

Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
by: Bin Lu, et al.
Published: (2021-10-01)

Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation
by: Laura Márquez-Cantudo, et al.
Published: (2021-09-01)

Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
by: Danishuddin, et al.
Published: (2023-11-01)

Pharmacophore-based ML model to filter candidate E3 ligands and predict E3 Ligase binding probabilities
by: Reagon Karki, et al.
Published: (2024-01-01)

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α
by: Mónica Cubillos-Rojas, et al.
Published: (2023-01-01)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
by: Chao Wang, et al.
Published: (2022-12-01)

PROTAC vaccine: A new way to live attenuated vaccines
by: Zhen Li, et al.
Published: (2022-10-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
by: Aleša Bricelj, et al.
Published: (2021-07-01)

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
by: Jing Liu, et al.
Published: (2021-07-01)

PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
by: Hiroyuki Inuzuka, et al.
Published: (2022-01-01)

Antiviral PROTACs: Opportunity borne with challenge
by: Jinsen Liang, et al.
Published: (2023-06-01)

Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs
by: Qiaohua Qin, et al.
Published: (2022-12-01)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
by: Mikihiko Naito, et al.
Published: (2019-12-01)